Tyler Van Buren
Stock Analyst at TD Cowen
(2.23)
# 1,456
Out of 4,479 analysts
48
Total ratings
43.75%
Success rate
-3.72%
Average return
Main Sectors:
33 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TECX Tectonic Therapeutic | Initiates: Buy | n/a | $15.84 | - | 1 | Jun 24, 2024 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Buy | n/a | $20.30 | - | 1 | May 15, 2024 | |
| GILD Gilead Sciences | Maintains: Buy | $90 → $85 | $68.40 | +24.27% | 4 | Apr 26, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,020 → $1,030 | $1,044.66 | -1.40% | 6 | Apr 24, 2024 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Outperform | $35 → $55 | $34.17 | +60.96% | 1 | Mar 1, 2024 | |
| CRSP CRISPR Therapeutics AG | Downgrades: Underperform | $30 | $53.12 | -43.52% | 2 | Dec 11, 2023 | |
| CRGX CARGO Therapeutics | Initiates: Outperform | n/a | $15.83 | - | 1 | Dec 5, 2023 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | n/a | $23.79 | - | 1 | Nov 29, 2023 | |
| ACLX Arcellx | Initiates: Outperform | n/a | $53.25 | - | 1 | Oct 30, 2023 | |
| APGE Apogee Therapeutics | Initiates: Outperform | n/a | $38.21 | - | 1 | Aug 8, 2023 | |
| MRNA Moderna | Downgrades: Market Perform | $145 → $125 | $117.07 | +6.77% | 5 | Aug 4, 2023 | |
| SLRN Acelyrin | Initiates: Outperform | n/a | $4.12 | - | 1 | May 30, 2023 | |
| TVTX Travere Therapeutics | Initiates: Outperform | $30 | $8.09 | +270.83% | 1 | May 22, 2023 | |
| KROS Keros Therapeutics | Initiates: Outperform | n/a | $42.81 | - | 1 | Feb 14, 2023 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | n/a | $24.91 | - | 1 | Feb 6, 2023 | |
| FATE Fate Therapeutics | Downgrades: Market Perform | n/a | $3.22 | - | 2 | Jan 6, 2023 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $70 | $34.80 | +101.15% | 1 | Aug 8, 2022 | |
| ZNTL Zentalis Pharmaceuticals | Initiates: Outperform | n/a | $3.57 | - | 1 | Jul 12, 2022 | |
| ARVN Arvinas | Initiates: Outperform | n/a | $24.85 | - | 1 | Dec 7, 2021 | |
| TYRA Tyra Biosciences | Initiates: Outperform | n/a | $16.70 | - | 1 | Oct 11, 2021 | |
| EPIX ESSA Pharma | Initiates: Overweight | n/a | $4.93 | - | 1 | Mar 4, 2021 | |
| ALGS Aligos Therapeutics | Initiates: Overweight | n/a | $0.40 | - | 1 | Nov 10, 2020 | |
| BGNE BeiGene | Downgrades: Underweight | n/a | $143.93 | - | 2 | Nov 6, 2020 | |
| INZY Inozyme Pharma | Initiates: Overweight | n/a | $4.42 | - | 1 | Aug 18, 2020 | |
| NRIX Nurix Therapeutics | Initiates: Overweight | n/a | $18.93 | - | 1 | Aug 18, 2020 | |
| PSTX Poseida Therapeutics | Initiates: Overweight | n/a | $3.02 | - | 1 | Aug 4, 2020 | |
| LPTX Leap Therapeutics | Initiates: Overweight | n/a | $1.69 | - | 1 | Jun 29, 2020 | |
| PLRX Pliant Therapeutics | Initiates: Overweight | n/a | $10.60 | - | 1 | Jun 29, 2020 | |
| GOSS Gossamer Bio | Initiates: Overweight | n/a | $0.96 | - | 1 | Apr 22, 2020 | |
| TBPH Theravance Biopharma | Maintains: Overweight | n/a | $8.32 | - | 1 | Feb 25, 2020 | |
| ADVM Adverum Biotechnologies | Reiterates: Overweight | $140 → $200 | $6.84 | +2,823.98% | 1 | Jan 13, 2020 | |
| OMER Omeros | Downgrades: Market Perform | n/a | $3.85 | - | 1 | Nov 2, 2017 | |
| TEVA Teva Pharmaceutical | Downgrades: Market Perform | n/a | $16.55 | - | 1 | Aug 4, 2017 |
Tectonic Therapeutic
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $15.84
Upside: -
NewAmsterdam Pharma Company
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $20.30
Upside: -
Gilead Sciences
Apr 26, 2024
Maintains: Buy
Price Target: $90 → $85
Current: $68.40
Upside: +24.27%
Regeneron Pharmaceuticals
Apr 24, 2024
Maintains: Buy
Price Target: $1,020 → $1,030
Current: $1,044.66
Upside: -1.40%
Biohaven Pharmaceutical Holding Company
Mar 1, 2024
Maintains: Outperform
Price Target: $35 → $55
Current: $34.17
Upside: +60.96%
CRISPR Therapeutics AG
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $53.12
Upside: -43.52%
CARGO Therapeutics
Dec 5, 2023
Initiates: Outperform
Price Target: n/a
Current: $15.83
Upside: -
Spyre Therapeutics
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $23.79
Upside: -
Arcellx
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $53.25
Upside: -
Apogee Therapeutics
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $38.21
Upside: -
Moderna
Aug 4, 2023
Downgrades: Market Perform
Price Target: $145 → $125
Current: $117.07
Upside: +6.77%
Acelyrin
May 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $4.12
Upside: -
Travere Therapeutics
May 22, 2023
Initiates: Outperform
Price Target: $30
Current: $8.09
Upside: +270.83%
Keros Therapeutics
Feb 14, 2023
Initiates: Outperform
Price Target: n/a
Current: $42.81
Upside: -
BridgeBio Pharma
Feb 6, 2023
Initiates: Outperform
Price Target: n/a
Current: $24.91
Upside: -
Fate Therapeutics
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $3.22
Upside: -
Immunocore Holdings
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $34.80
Upside: +101.15%
Zentalis Pharmaceuticals
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $3.57
Upside: -
Arvinas
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $24.85
Upside: -
Tyra Biosciences
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $16.70
Upside: -
ESSA Pharma
Mar 4, 2021
Initiates: Overweight
Price Target: n/a
Current: $4.93
Upside: -
Aligos Therapeutics
Nov 10, 2020
Initiates: Overweight
Price Target: n/a
Current: $0.40
Upside: -
BeiGene
Nov 6, 2020
Downgrades: Underweight
Price Target: n/a
Current: $143.93
Upside: -
Inozyme Pharma
Aug 18, 2020
Initiates: Overweight
Price Target: n/a
Current: $4.42
Upside: -
Nurix Therapeutics
Aug 18, 2020
Initiates: Overweight
Price Target: n/a
Current: $18.93
Upside: -
Poseida Therapeutics
Aug 4, 2020
Initiates: Overweight
Price Target: n/a
Current: $3.02
Upside: -
Leap Therapeutics
Jun 29, 2020
Initiates: Overweight
Price Target: n/a
Current: $1.69
Upside: -
Pliant Therapeutics
Jun 29, 2020
Initiates: Overweight
Price Target: n/a
Current: $10.60
Upside: -
Gossamer Bio
Apr 22, 2020
Initiates: Overweight
Price Target: n/a
Current: $0.96
Upside: -
Theravance Biopharma
Feb 25, 2020
Maintains: Overweight
Price Target: n/a
Current: $8.32
Upside: -
Adverum Biotechnologies
Jan 13, 2020
Reiterates: Overweight
Price Target: $140 → $200
Current: $6.84
Upside: +2,823.98%
Omeros
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $3.85
Upside: -
Teva Pharmaceutical
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $16.55
Upside: -